¿Àµµ¿¬
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : Ç÷¾×, Ç÷ÀüÁöÇ÷
Á÷
ˤ
: ±³¼ö
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
176
ÇØ¿Ü
1. Jeon YJ, Kim JW, Park HM, Jang HG, Kim JO, Oh J, Chong SY, Kwon SW, Kim EJ, Oh D, Kim NK. Interplay between 3"-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans. BMC Cancer.2014;14:881.
175
ÇØ¿Ü
Ageno W, Di Minno MN, Ay C, Jang MJ, Hansen JB, Steffen LM, Vayà A, Rattazzi M, Pabinger I, Oh D, Di Minno G, Braekkan SK, Cushman M, Bonet E, Pauletto P, Squizzato A, Dentali F. Association between the metabolic syndrome, its individual components, and unprovoked venous thromboembolism: results of a patient-level meta-analysis. Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2478-85.
174
ÇØ¿Ü
Seo JY, Lee KO, Kim SH, Oh D, Kim DK, Kim HJ. The genomic architecture of the PROS1 gene underlying large tandem duplication mutation that causes thrombophilia from hereditary protein S deficiency. Gene. 2014 Sep 1;547:295-9.
173
ÇØ¿Ü
Ageno W, Riva N, Schulman S, Bang SM, Sartori MT, Grandone E, Beyer-Weisendorf J, Barillari G, Di Minno MN, Dentali F, IRSVT study group. Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. Semin Thromb Hemost 2014 Feb 40(1):99-105
172
ÇØ¿Ü
Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism N Engl J Med. 2013 Oct 10;369(15):1406-15.
171
ÇØ¿Ü
Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013 Feb 7;368(6):513-23
170
ÇØ¿Ü
Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C; RE-COVER II Trial Investigators. Treament of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014 Feb 18;129(7):764-72
169
ÇØ¿Ü
Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin or placebo in venous thromboembolism. N Engl J Med 2013 Feb 21; 368(8):709-18
168
±¹³»
Oh D, Jeong MH, Park R. The official journal of the Korean Society on Thrombosis and Hemostasis from KJHT to CETH. Clin Ext Thromb Hemost 2014 1(1):3
167
±¹³»
Oh J, Choi MC, Park H, Lee C, Lee JM, Chong SY, Oh D. Preoperative thrombocytosis is an independent poor prognostic factor in patients with epithelial ovarian cancer. Clin Ext Thromb Hemost 2014 1(1):17-21
1
2
3
4
5
6
7
8
9
10
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729